Evidence map›Paper›PMID 40125138›Full record

ReviewCureus2025

Artificial Intelligence and Early Detection of Breast, Lung, and Colon Cancer: A Narrative Review.

Omofolarin Debellotte, Richard L Dookie, Fnu Rinkoo, Akankshya Kar, Juan Felipe Salazar González, Pranav Saraf, Muhammed Aflahe Iqbal, Lilit Ghazaryan, Annie-Cheilla Mukunde, Areeba Khalid and 1 more

Abstract readReview
In one paragraph

Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Omofolarin DebellotteInternal Medicine, Brookdale Hospital Medical Center, One Brooklyn Health, Brooklyn, USA.
Richard L DookieInternal Medicine, Landmark Medical Center, Woonsocket, USA.
Fnu RinkooMedicine and Surgery, Ghulam Muhammad Mahar Medical College, Sukkur, PAK.
Akankshya KarInternal Medicine, SRM Medical College Hospital and Research Centre, Chennai, IND.
Juan Felipe Salazar GonzálezGeneral Medicine, Clínica Renovar, Villavicencio, COL.
Pranav SarafInternal Medicine, SRM Medical College and Hospital, Chennai, IND.
Muhammed Aflahe IqbalInternal Medicine, Muslim Educational Society (MES) Medical College Hospital, Perinthalmanna, IND.
Lilit GhazaryanMedicine, Yerevan State Medical University, Yerevan, ARM.
Annie-Cheilla MukundeInternal Medicine, Escuela de Medicina de la Universidad de Montemorelos, Montemorelos, MEX.
Areeba KhalidRespiratory Medicine, Sikkim Manipal Institute of Medical Sciences, Gangtok, IND.
Toluwalase OlumuyiwaMedicine, Allsaints University School of Medicine, Roseau, DMA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Artificial intelligence (AI) is revolutionizing early cancer detection by enhancing the sensitivity, efficiency, and precision of screening programs for breast, colorectal, and lung cancers. Deep learning algorithms, such as convolutional neural networks, are pivotal in improving diagnostic accuracy by identifying patterns in imaging data that may elude human radiologists. AI has shown remarkable advancements in breast cancer detection, including risk stratification and treatment planning, with models achieving high specificity and precision in identifying invasive ductal carcinoma. In colorectal cancer screening, AI-powered systems significantly enhance polyp detection rates during colonoscopies, optimizing the adenoma detection rate and improving diagnostic workflows. Similarly, low-dose CT scans integrated with AI algorithms are transforming lung cancer screening by increasing the sensitivity and specificity of early-stage cancer detection, while aiding in accurate lesion segmentation and classification. This review highlights the potential of AI to streamline cancer diagnosis and treatment by analyzing vast datasets and reducing diagnostic variability. Despite these advancements, challenges such as data standardization, model generalization, and integration into clinical workflows remain. Addressing these issues through collaborative research, enhanced dataset diversity, and improved explainability of AI models will be critical for widespread adoption. The findings underscore AI's potential to significantly impact patient outcomes and reduce cancer-related mortality, emphasizing the need for further validation and optimization in diverse healthcare settings.

Indexed as

artificial intelligenceartificial intelligence in medicinebreast cancer detectioncolon cancer detectionlung cancer detection

Identifiers

PMID40125138
PMCPMC11926462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.